New Eloxatin® and TAXOTERE® Research to be Presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
New Eloxatin® and TAXOTERE® Research to be Presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) ~ More than 200 Studies of Two Leading Chemotherapy Treatments in some of the Most Common and Difficult to Treat Cancers to be Featured at the Meeting ~ Paris, May 10, 2005 – The sanofi-aventis Group announced today that important results from Eloxatin® (oxaliplatin for injection) and Taxotere® (docetaxel) Injection Concentrate clinical studies, including studies on colorectal, breast, lung, prostate and gastric cancer, will be presented at the 41st Annual Meeting